DLD-1-luc Orthotopic Mouse Model Service for Colon Cancer

The DLD-1-luc orthotopic mouse model integrates a luciferase-reporter human colorectal adenocarcinoma cell line with anatomically faithful cecal wall implantation, enabling non-invasive, longitudinal visualization of tumor establishment, local progression, and therapeutic response within a physiologically relevant colon microenvironment. Alfa Cytology constructs and manages this model with authenticated DLD-1-luc cell assets, refined surgical protocols, and integrated bioluminescence imaging infrastructure, furnishing investigators with a robust platform for preclinical evaluation of targeted agents, combination regimens, and locoregional therapeutic strategies against colorectal malignancy.

Overview of DLD-1-luc Orthotopic Mouse Model for Colon Cancer

The DLD-1 cell line was originally isolated by D.L. Dexter and colleagues in 1977 from a Dukes' type C colorectal adenocarcinoma resected from a 67-year-old male patient. This line harbors a characteristic mutational repertoire that mirrors the most prevalent molecular subtype of sporadic colorectal cancer: a heterozygous KRAS G13D activating mutation, biallelic PIK3CA alterations (E545K and D549N), a TP53 S241F missense mutation, and a truncating APC frameshift. Classified as microsatellite unstable (MSI-H) and chromosomally instable (CIN), DLD-1 cells exhibit an epithelial cobblestone morphology, express carcinoembryonic antigen (CEA), and display a doubling time of approximately 20–24 hours under standard culture conditions. The luciferase-transduced derivative, DLD-1-luc, retains the full parental genetic identity while constitutively expressing firefly luciferase, permitting quantitative photon flux readouts that correlate with viable tumor burden in vivo.

Fig 1. Longitudinal IVIS monitoring of DLD-1 clone#1-Luc colorectal tumors in mice, enabling quantitative tracking of tumor burden through luciferase-derived bioluminescence. Arima, Jun, et al., 2023)

Orthotopic engraftment of DLD-1-luc cells into the murine cecal wall recapitulates the histoarchitectural context of human colorectal carcinoma, including luminal-stromal interactions, submucosal vascular networks, and peritoneal surface topology. This configuration supports the formation of well-differentiated glandular tumors that maintain KRAS-driven signaling and APC/β-catenin pathway dysregulation, providing a translationally grounded substrate for testing anti-EGFR therapeutics, MEK inhibitors, and PI3K pathway antagonists. The built-in luciferase reporter further enables serial, non-invasive quantification of tumor dynamics without repeated surgical intervention, making this model particularly advantageous for kinetic pharmacodynamic studies and early efficacy screening of novel compounds directed against KRAS-mutant colorectal cancer.

Cell Line Information: DLD-1-luc

The table below compiles the essential biological, genetic, and technical specifications of the DLD-1-luc cell line, offering a detailed reference for investigators designing preclinical colon cancer studies in both in vitro and in vivo settings.

Our Services

Alfa Cytology delivers a comprehensive DLD-1-luc orthotopic mouse model service engineered for high-fidelity preclinical colon cancer research. Our offering encompasses authenticated luciferase-expressing cell line sourcing, mycoplasma screening, and expansion under rigorously controlled passage limits, followed by precision cecal wall surgical implantation in immunocompromised hosts. Longitudinal tumor monitoring is conducted via IVIS bioluminescence imaging at customizable intervals, while endpoint analyses span tumor biometrics, histopathology, immunohistochemistry, and molecular profiling. Every study parameter—from implantation cell density to imaging schedules and tissue harvest protocols—is calibrated to your compound mechanism and translational objectives, ensuring data packages that withstand peer-review scrutiny and regulatory documentation standards.

Workflow of DLD-1-luc Orthotopic Mouse Model Construction

Establishment of the DLD-1-luc orthotopic model demands meticulous attention to cell line integrity, surgical sterility, and imaging standardization to achieve consistent engraftment and quantifiable therapeutic readouts. The protocol outlined below reflects a validated operational framework executed within barrier-maintained vivaria, progressing through the following sequential stages:

1. Cell Line Authentication and Luciferase Validation: DLD-1-luc cells are revived from cryopreserved master stocks and expanded in RPMI 1640 supplemented with 10% FBS. Prior to surgical use, cells undergo STR identity confirmation, mycoplasma PCR screening, and in vitro luciferase activity quantification via D-luciferin substrate assay to verify reporter expression stability and signal linearity across the anticipated cell density range.
2. Host Selection and Preoperative Conditioning: Female athymic nude (nu/nu) or NOD/SCID gamma (NSG) mice aged 6–8 weeks are selected based on study design and compound immunogenicity considerations. Animals are acclimated for a minimum of five days under specific pathogen-free conditions with controlled temperature (22 ± 2°C), humidity (50 ± 10%), and 12-hour light/dark cycle, with ad libitum access to irradiated chow and acidified water.
3. Anesthesia and Abdominal Surgical Preparation: On the day of implantation, mice are anesthetized with 2–3% isoflurane inhalation, with anesthetic depth verified by absence of pedal withdrawal reflex. The ventral abdominal fur is removed and the skin is disinfected with sequential povidone-iodine and 70% ethanol applications. Sterile surgical drapes are positioned to establish an aseptic operative field.
4. Cecal Exposure and Orthotopic Cell Delivery: A 1.0–1.5 cm midline laparotomy is performed to access the peritoneal cavity. The cecum is gently exteriorized using atraumatic forceps and maintained in a hydrated state with warm sterile PBS. A single-cell suspension of 2 × 10⁶ viable DLD-1-luc cells, resuspended in 25–50 µL of serum-free RPMI 1640 mixed 1:1 with growth factor-reduced Matrigel, is loaded into a 1 mL syringe with a 30 G needle. The needle is inserted into the subserosal plane of the cecal wall at the anti-mesenteric border, and the cell suspension is slowly deposited to form a discrete submucosal bleb without mucosal perforation.
5. Hemostasis, Cecal Repositioning, and Wound Closure: The injection site is compressed with a sterile cotton swab for approximately 3 minutes to ensure hemostasis and prevent cell leakage into the peritoneal cavity. The cecal wall is inspected for integrity, then gently returned to anatomical position within the abdomen. The abdominal musculature is closed with absorbable 5-0 sutures in a continuous pattern, and the skin is apposed with surgical staples or tissue adhesive. Mice are placed in a warmed recovery chamber and monitored until complete ambulatory recovery.
6. Bioluminescence Imaging and Tumor Kinetics Monitoring: Beginning approximately 7–10 days post-implantation, tumor establishment is monitored via non-invasive bioluminescence imaging. Mice receive an intraperitoneal injection of D-luciferin (150 mg/kg) and are imaged under isoflurane anesthesia using an IVIS spectrum system. Photon flux (photons/sec) is quantified within a standardized region of interest, with imaging frequency adjusted to study design—typically twice weekly during the growth phase and weekly during treatment phases.
7. Stratified Randomization and Therapeutic Administration: Once tumors achieve a predetermined bioluminescence signal intensity—typically 10⁶ to 10⁷ photons/sec—mice are stratified by tumor burden and body weight into treatment and vehicle control cohorts. Investigational compounds are administered according to predefined dosing regimens, with routes selected based on pharmacokinetic properties. Concurrent bioluminescence imaging continues to capture real-time therapeutic response kinetics.
8. Necropsy, Triage, and Multi-Platform Endpoint Analysis: At study termination, mice are humanely euthanized under deep anesthesia. The cecum and primary tumor are excised, photographed, and weighed. Tumor tissue is triaged for formalin fixation and paraffin embedding (H&E, IHC for Ki-67, CD31, cleaved caspase-3), snap-freezing for Western blot or RNA-seq, and dissociation for flow cytometric analysis. Ex vivo bioluminescence imaging of excised organs confirms metastatic dissemination to mesenteric lymph nodes, liver, and lung, with histological confirmation of all macroscopic lesions.

Fig 2. DLD-1-luc Orthotopic Mouse Model construction workflow.

Case Study-DLD-1-luc Orthotopic Mouse Model Development

In a recent preclinical investigation, the DLD-1-luc orthotopic model was deployed to evaluate the efficacy of a KRAS G13D-targeted small-molecule inhibitor administered as monotherapy and in combination with a PI3Kα-selective antagonist. Following cecal wall implantation, tumor-bearing mice were stratified by bioluminescence signal and randomized into treatment arms. Longitudinal in vivo imaging revealed a progressive decline in photon flux within the combination cohort beginning at day 14 post-treatment initiation, whereas monotherapy arms showed partial stabilization. Terminal histopathological analysis demonstrated reduced Ki-67 proliferation indices and increased apoptotic fractions in combination-treated tumors, alongside attenuated phospho-ERK and phospho-AKT immunoreactivity. These data illustrate the utility of the DLD-1-luc orthotopic platform for discriminating combination synergy from single-agent activity and for generating mechanistic insights into KRAS/PI3K co-inhibition in colorectal adenocarcinoma.

Why Choose Alfa Cytology?

Engaging Alfa Cytology for your DLD-1-luc orthotopic model program confers access to a specialized preclinical service architecture optimized for precision oncology research. Our competitive differentiators include:

• Authenticated DLD-1-luc master cell banks with documented STR profiles, mycoplasma negativity, and sustained luciferase expression stability across extended passage ranges.
• Standardized in vitro luciferase validation assays ensuring linear signal-to-cell-number correlation prior to in vivo deployment, safeguarding quantitative imaging fidelity.
• Experienced microsurgical teams proficient in cecal wall orthotopic implantation with high engraftment consistency and minimal perioperative complications.
• On-site IVIS bioluminescence imaging capability enabling scheduled longitudinal tumor monitoring with calibrated photon flux quantification and automated region-of-interest analysis.
• Flexible study architectures accommodating monotherapy, combination, and sequential dosing designs with stratified randomization based on real-time tumor burden metrics.
• Comprehensive endpoint triage protocols delivering parallel histopathological, immunohistochemical, molecular, and flow cytometric datasets from a single tumor specimen.

Contact Us

If your preclinical pipeline demands a rigorously validated DLD-1-luc orthotopic model with integrated bioluminescence imaging and multi-parametric endpoint capabilities, the scientific team at Alfa Cytology is prepared to architect a study plan tailored to your therapeutic target and translational milestones. Contact us today to discuss your project scope, obtain a detailed service quotation, or schedule a technical briefing with our colon cancer model specialists.

For research use only. Not intended for any clinical use.